Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 28:13:e19235.
doi: 10.7717/peerj.19235. eCollection 2025.

Effects of bortezomib on intracellular antioxidant and apoptosis in HepG2cells

Affiliations

Effects of bortezomib on intracellular antioxidant and apoptosis in HepG2cells

Grażyna Świderska-Kołacz et al. PeerJ. .

Abstract

Bortezomib, as a proteasome inhibitor, is used in clinical trials related to solid cancers. However, its use is not always associated with a good response to treatment. Taking into account the above, we decided to analyze the effect of the time-dependency (24 vs. 48 h) and the dose-dependency of bortezomib (2, 4, 8 and 16 nM) on apoptosis and activities of antioxidant enzymes such as catalase (CAT), superoxide dismutase (SOD), glutathione reductase (GR), glutathione peroxidase (GPx) and glutathione transferase (GST), as well as concentrations of reduced glutathione (GSH) and malondialdehyde (MDA) in hepatoblastoma cell line (HepG2) cells. We have shown that increasing concentrations of bortezomib caused (I) a gradual decrease in the levels of GSH; (II) changes in MDA concentrations and antioxidant enzymes activities; (III) increase in apoptosis levels in HepG2 cells. We did not find significant association between antioxidant parameters and number of apoptotic cells. Our study showed that the analyzed parameters (such as: CAT, SOD, GR, GPx, GST, GSH, MDA) changed after bortezomib treatment. It is important to search for new anti-cancer therapies based on next-generation proteasome inhibitors. It is possible that the use of proteins associated with oxidative stress will help enhance the action of these inhibitors and will provide a better treatment effect.

Keywords: Apoptosis; Bortezomib; HepG2 cells; Oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare there are no competing interests.

Figures

Figure 1
Figure 1. Flow cytometry analysis of apoptosis in HepG2 cells treated with 2 nM and 16 nM of bortezomib.
Control for (A) 24 h; (B) 48 h; the cells treated with 2 nM of bortezomib for (C) 24 h, (D) 48 h; and 16 nM of bortezomib (C) for 24 h and, (D) 48 h.
Figure 2
Figure 2. The cell viability obtained by MTT after 24 (green) and 48 (blue) h of treatment with bortezomib.
(A) The cell viability obtained by MTT after 24 h of treatment with bortezomib. (B) The cell viability obtained by MTT after 48 h of treatment with bortezomib.
Figure 3
Figure 3. The cell viability obtained by MTT after 24 and 48 h of treatment with bortezomib.
(A) The cell viability obtained by MTT after 24 h of treatment with bortezomib. (B) The cell viability obtained by MTT after 48 h of treatment with bortezomib.
Figure 4
Figure 4. Canonical correspondence analysis.
Canonical correspondence analysis of data on the dependence of apoptosis rate on time and bortezomib concentration. Variables significant for the variability in the data set are marked in red (Monte Carlo Permutation Test, p < 0.05).

Similar articles

References

    1. Abou-Ghali M, Stiban J. Regulation of ceramide channel formation and disassembly: insights on the initiation of apoptosis. Saudi Journal of Biological Science. 2015;22(6):760–772. doi: 10.1016/j.sjbs.2015.03.005. - DOI - PMC - PubMed
    1. Akhigbe RE, Oluwole DT, Adegoke TE, Hamed MA, Anyogu DC, Ajayi AF. Suppression of glutathione system and upregulation of caspase 3-dependent apoptosis mediate rohypnol-induced gastric injury. Redox Report. 2022;27(1):111–118. doi: 10.1080/13510002.2022.2074128. - DOI - PMC - PubMed
    1. Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis 24. 2018;7(1):8. doi: 10.1038/s41389-017-0025-3. - DOI - PMC - PubMed
    1. Augello G, Modica M, Azzolina A, Puleio R, Cassata G, Emma MR, Di Sano C, Cusimano A, Montalto G, Cervello M. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells. Cell Death & Disease. 2018;9(2):28. doi: 10.1038/s41419-017-0195-0. - DOI - PMC - PubMed
    1. Aykin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz RW. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochemical Journal. 2009;418(1):29–37. doi: 10.1042/BJ20081258. - DOI - PMC - PubMed

MeSH terms